Clinical Trial Detail

NCT ID NCT02576496
Title Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Mundipharma-EDO GmbH
Indications

Hodgkin's lymphoma

Waldenstroem's macroglobulinemia

hematologic cancer

multiple myeloma

prolymphocytic leukemia

peripheral T-cell lymphoma

non-Hodgkin lymphoma

Therapies

Tinostamustine

Age Groups: adult senior

No variant requirements are available.